Equities research analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a report issued on Thursday. The firm set a "hold" rating on the stock.
Separately, JMP Securities reissued a "market outperform" rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.
Get Our Latest Stock Analysis on DBVT
DBV Technologies Price Performance
Shares of DBV Technologies stock traded up $0.21 on Thursday, reaching $9.46. The company had a trading volume of 53,787 shares, compared to its average volume of 185,011. The firm's 50-day moving average price is $6.58 and its two-hundred day moving average price is $4.75. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.90. The firm has a market cap of $259.11 million, a price-to-earnings ratio of -2.10 and a beta of -0.66.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. As a group, analysts anticipate that DBV Technologies will post -7.05 EPS for the current year.
Institutional Investors Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). 71.74% of the stock is owned by institutional investors and hedge funds.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Further Reading
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
